Back to User profile » Dr Zhaohui Arter
Papers published by Dr Zhaohui Arter:
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
Aldecoa KAT, Arter ZL, Ou SHI, Nagasaka M
Lung Cancer: Targets and Therapy 2026, 17:592922
Published Date: 28 May 2026
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report
Nagasaka M, Arter ZL, Park CJ, Sarkari A, Ou SI
Lung Cancer: Targets and Therapy 2026, 17:600499
Published Date: 14 May 2026
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
Lee ATM, Park CJ, Arter ZL, Nagasaka M, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:199-203
Published Date: 25 December 2025
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
Ou SHI, Park CJ, Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2025, 16:139-145
Published Date: 22 October 2025
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Luo FX, Arter Z, Ou SI, Nagasaka M
Lung Cancer: Targets and Therapy 2025, 16:51-55
Published Date: 25 April 2025
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
Arter ZL, Shieh K, Nagasaka M, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:1-9
Published Date: 19 February 2025
Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
Luo FX, Arter ZL
Lung Cancer: Targets and Therapy 2024, 15:161-167
Published Date: 30 October 2024
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:129-133
Published Date: 28 August 2024
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:115-121
Published Date: 9 July 2024
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:1-8
Published Date: 25 January 2024
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Brazel D, Arter Z, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:75-80
Published Date: 10 November 2022